which 17 (18 %) had an IDH1 mutation. PFS6 was seen in 26/49 (53 %) patients. IDH status was unknown in two of these patients. 5/24 (21 %) were IDH1 mutated compared to 5/24 (21 %) of their matched cohort without PFS6. RR was found in 47/49 (94 %) patients. IDH status was unknown in four of these patients. IDH1 mutation was present in 7/43 (16 %) patients with RR compared to 10/43 (23 %) in the matched cohort without RR (p = 0.48). Median OS for trials at first recurrence was 9.8 months for IDH1 wildtype GB vs. 19.32 months for IDH1 mutated GB (p = 0.14). IDH1 mutation status was not predictive of PFS6 or RR in recurrent GB trials for this data set. However, further examination in larger randomized prospective studies is needed.
Introduction
Glioblastoma (GB) is the most common malignant primary brain tumor in adults [1] . Overall median survival for pts with GB treated with maximal resection, 6 weeks of concurrent chemoradiation with daily temozolomide followed by 6-12 cycles of adjuvant temozolomide is approximately 16 months [2] . Although bevacizumab is approved for recurrent disease, treatment with clinical trials is recommended.
GB historically has been classified as primary GB if it develops de novo or as secondary GB if it progresses clinically from a low-grade or anaplastic astrocytoma [3] . The histopathologic findings for primary and secondary GBs are indistinguishable (consisting of microvascular proliferation or necrosis). Secondary GB occurs less frequently (~5 % of GBs) and typically in younger pts (median age ~45 years vs. ~60 years for primary GB) [4] . However, the prognosis of Abstract IDH1 mutated glioblastoma (GB) has a better prognosis than IDH1 wildtype GB. However, it remains unknown whether patients (pts) with IDH1 mutated GB have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate on clinical trials for recurrence. Retrospective review of GB pts at MDACC between 2006 and 2012 identified 330 patients in recurrent GB trials. 93 patients (28 %) had either PFS6 or a complete/partial RR per RANO criteria. 49/93 (53 %) patients with PFS6 or a complete/partial RR had tumor tissue for IDH1 testing. A matched cohort of 49 patients on recurrent GB clinical trials that failed to achieve PFS6 or RR (also with tissue for IDH1 testing) was identified for comparison. IDH1 status was obtained in 92/98 (94 %) patients of trial, type of chemotherapies and/or targeted therapies used on recurrent GB trial, number of chemotherapy regimens tried prior to start of recurrent GB trial, PFS on recurrent GB trial, imaging response on recurrent GB clinical trial per RANO criteria [15] , date of imaging response, date of death and/or last follow up.
For pts with a previous diagnosis of a lower grade tumor (low grade or anaplastic glioma), additional data was collected including date of initial tumor diagnosis, histopathologic grade of initial tumor, extent of resection at initial tumor diagnosis, and KPS at initial tumor diagnosis.
93 patients (28 %) on recurrent GB trials were found to have had either a PFS6 or a complete or partial RR per RANO criteria. Of these 93 patients, 49 (53 %) were found to have tumor tissue available for IDH1 testing. These 49 patients were then matched by protocol, age and KPS to 49 of the 237 patients on recurrent GB trials that did not have a PFS6 or RR for a total study cohort of 98 patients (Fig. 1) .
IDH1 mutation testing was performed by immunohistochemistry. Immunohistochemistry was manually performed with anti-IDH1-R132H mouse anticlonal antibody (Dianova, Hamburg, Germany, clone H09, dilution 1:200). All controls were appropriate. Two experienced neuropathologists (K.A. and G.F.) were blinded from previously obtained clinical data and independently analyzed the tissue samples.
Statistical analysis
Patient demographic and clinic-pathological characteristics such as age, performance status (KPS), extent of surgical resections, grades of tumors were summarized as a whole and by IDH groups, using standard descriptive statistics and frequency tabulation. Chi squared test or Fisher's exact test were used to test the any difference of categorical variables between IDH groups. PFS and overall survival from initial diagnosis, GB diagnosis and start of recurrent GB trial were estimated using the Kaplan-Meier method and the comparisons between IDH groups were assessed using log-rank test. Multicovariate Cox proportional hazard models were applied to assess the effect of covariates of interest (age, grade, extent of surgical resections, KPS at initial tumor diagnosis and/or GBM diagnosis, and IDH1 status) on PFS and overall survival. All computations were carried out in SAS 9.3 (SAS Institute Inc., Cary, NC, USA) and Splus 8.2 (TIBCO Software Inc, Palo Alto, CA) or R 2.15.1.
Results
Median age at GB diagnosis was 48.2 years (range 19.3-78.6). Median time from GB diagnosis to recurrent GB clinical trial was 9.7 months. KPS prior to enrollment on primary and secondary GB does not appear to be different after adjustment for age [5] and recurrent GBs clinical trials currently do not stratify pts based upon this distinction.
Recently, molecular profiling is being utilized to separate diffuse gliomas including GB into prognostic groups [6, 7] . A mutation affecting codon 132 of the isocitrate dehydrogenase 1 (IDH1) gene was found to occur in up to 12 % of GBs [8, 9] . A review of sequencing studies on large glioma patient cohorts have found IDH1 mutations present in 6 % (range 3-16) of clinically defined primary GB and 76 % (range 73-88) of clinically defined secondary GB [10] .
However, IDH1 mutation is now considered the definitive diagnostic molecular marker of secondary GBs and is considered more reliable and objective than clinical criteria [11] . Long term outcome for pts with high-grade glioma including GB directly correlates with IDH1 mutation status. IDH1 mutated tumors have been associated with an improved outcome comparable to IDH1 wild-type tumors [12, 13] . IDH1 mutation has remained an independent favorable prognostic marker even after adjustment for age, grade, MGMT status, genomic profile, and treatment in multivariate analysis [14] .
Despite IDH1 mutated tumors being associated with an improved outcome, clinical trials for recurrent GB currently do not stratify pts based upon IDH status. Historically, the PFS6 rate for recurrent GB trials is approximately 9-12 % which could be similar to the estimated percentage of pts on clinical trials expected by chance to have IDH1 mutated tumors. It remains unknown if pts with IDH1 mutated GB on clinical trials are more likely to have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate.
The goal of this study was to examine if pts on recurrent GB trials with PFS6 and/or RR were more likely to have an IDH1 mutation and thus require future recurrent GB clinical trials to stratify or exclude pts with IDH1 mutation.
Methods

Patients
After obtaining institutional board review approval (protocol PA12-0938), we retrospectively identified 330 GB patients treated at MD Anderson on clinical trials for recurrent disease from 2006 to 2012 in our institutional database. All of the pts had a pathologically-confirmed diagnosis of GB using World Health Organization (WHO) criteria.
Data was then collected on all pts including date of birth, date of GB diagnosis, extent of resection at GB diagnosis as determined by imaging or operative reports if imaging was not available, Karnofsky performance status score (KPS) at GB diagnosis and recurrent GB trial, date of recurrent GB but had stable imaging). IDH1 mutation status was indeterminate in four pts with RR. IDH1 mutation was present in 7/43 (16 %) patients with RR compared to 10/43 (23 %) patients of their matched cohort without RR (p = 0.48).
PFS6 was seen in 26/49 (53 %) patients. IDH1 mutation status was incomplete in two pts. 5/24 (21 %) patients with PFS6 had IDH1 mutations compared to 5/24 (21 %) patients of their matched cohort without PFS6 (p = 1.0).
Prior diagnosis of low grade or anaplastic glioma
Prior diagnosis of low grade or anaplastic glioma was found in 23 % (23/98) of patients of which 13 (57 %) were initially diagnosed as low grade and ten as anaplastic.
Prior diagnosis of low grade or anaplastic glioma was seen in 18 % (9/49) of pts with PFS6 and/or RR compared to 29 % of pts (14/49) in the matched cohort without PFS6 or RR.
Initial tumor diagnosis in the PFS6 and/or RR cohort included three anaplastic astrocytomas, an infiltrating diffuse glioma, a low grade oligodendroglioma, a low grade oligoastrocytoma, and three low grade astrocytomas.
Initial tumor diagnosis in the matched cohort without PFS6 or RR included six anaplastic astrocytomas, an recurrent GB trial was equal to or greater than 90 in 34.7 % of patients (Table 1) .
Recurrent GB trial was at first-fourth tumor recurrence from GB diagnosis with 62 % of trials at the first recurrence, 26 % at second, 8 % at third and 4 % at fourth recurrence. Median OS for pts on trial for first recurrence was 11.5 months, second recurrence 8.11 months, third recurrence 6.44 months, and fourth recurrence 5.67 months (p = 0.17). Recurrent GB trial was at first recurrence in 30 patients (61 %) with PFS6 and/or RR compared to 31 patients (63 %) in the matched cohort of pts that that failed to achieve PFS6 or RR. Median time from GB diagnosis to recurrent GB trial for the cohort of pts with PFS6 and/or RR was 9.79 months and 8.44 months for the cohort of pts without PFS6 or RR (p = 0.60).
The most common recurrent trial consisted of a bevacizumab containing regimen (38 %), followed by XL-184 (cabozantinib, Exelixis; 22 %), temozolomide containing regimen (12 %), carboplatin containing regimen (10 %), lapatinib and pazopanib (8 %), other (6 %) and VEGF trap (4 %) (Supplementary Table 1) .
Of the 49 patients in the cohort with PFS6 and/or RR, RR consisted of a partial response in 45 patients and complete response in two pts (the other two pts had PFS6 without RR Of the lower grade tumors, 7/12 (58 %) were IDH1 mutated (1 unknown) and of the anaplastic glioma 4/9 (44 %) were IDH1 mutated (1 unknown). Median OS from initial tumor diagnosis for low grade or anaplastic glioma was 36.3 months for IDH1 wildtype tumors vs. 82.7 months for IDH1 mutated tumors (p = 0.0327).
Median time from low grade or anaplastic glioma diagnosis to GB diagnosis was 35.9 months (range 6.7-218.4). Median time from low grade or anaplastic glioma diagnosis to GB diagnosis for IDH1 mutated tumors was 66.4 months (range 17.7-218.4) and 16 months (range 7.6-167.4) for IDH1 wildtype tumors (p = 0.01) (Fig. 2b) .
KPS at GB diagnosis was greater than 80 in 78.6 % of patients (77/98) with no difference in KPS between IDH1 mutated and IDH1 wildtype tumors (p = 0.94). Median overall survival from GB diagnosis was 20.6 months for IDH1 wildtype tumors vs. 25.0 months for IDH1 mutated tumors (p = 0.097). Median overall survival from GB diagnosis for tumors with initial diagnosis of GB was 20.8 months for anaplastic oligodendroglioma, a low grade oligoastrocytoma, a low grade oligodendroglioma, and five low grade astrocytomas.
IDH1 mutation status
IDH1 status was obtained in 92 (94 %) patients of which 17 (18 %) had an IDH1R132H mutation. IDH1 mutation was seen in 8 % (6/71) of pts with initial diagnosis of GB (four unknown) and 52 % (11/21) of GB pts with a prior diagnosis of low grade or anaplastic glioma (two unknown). Median age at initial tumor diagnosis for IDH1 mutated tumors was 34.9 years (range 23.3-56.3) and 52.7 years (range 19.3-77.4) for IDH1 wildtype tumors (p = 0.0001). Median overall survival (OS) from initial tumor diagnosis was 22 months for IDH1 wildtype tumors vs. 83 months for IDH1 mutated tumors (p < 0.0001) (Fig. 2a) . IDH1 mutation status as a prognostic marker remained significant in multivariate analysis (p = 0.0005) ( . Although this finding is quite limited due to the very small number (n = 5) on GB trials at first recurrence with IDH1 mutations, it is consistent with the results of the BELOB study which limited pts to first recurrence and found a median overall survival of 9 months in IDH wild-type tumors vs. 20 months in IDH mutant tumors [16] . These results suggest that stratification of pts based on IDH mutation status could be necessary for recurrent GB clinical trials that limit patient enrollment to first recurrence. However, further validation is required in larger randomized prospective trials. Prior studies have suggested that IDH1 mutations are very early events in gliomagenesis making them an appealing potential therapeutic target [17] . Additionally, an inhibitor of mutant IDH1 has demonstrated ability to delay growth and promote differentiation of glioma cells in murine models [18] . While our study confirmed IDH1 mutation status as strong prognostic marker of survival at initial tumor diagnosis (22 months for IDH1 wildtype tumors vs. 83 months for IDH1 mutated tumors; p < 0.0001), this benefit did not seem to persist at the time of recurrent GB trials (median OS on recurrent GB trial was 8.64 months for IDH1 wildtype GB vs. 9.59 months for IDH1 mutated GB; p = 0.49). This suggests that the biology of IDH1 mutated and wild type tumors may converge to the extent that IDH1 is no longer a driver mutation at the time of recurrent GB trials. From this it is possible to speculate that IDH1 inhibitors may be less likely to show efficacy in future clinical trials if used in recurrent GB trials compared to being started earlier in the course of the disease.
IDH1 mutations were present in 18 % of GB pts in our study which is slightly higher than seen in previous literature [8, 9] . This is presumed to be due to the high incidence (23 %) of secondary GBs included in our study. We suspect that the higher rate of secondary GBs is likely related to referral bias to MD Anderson Cancer Center as a specialized tertiary care facility. IDH1 mutations were seen in 8 % of pts with primary GB and 52 % of secondary GB in our study. This is consistent with a review of prior studies that reported an IDH1 mutation rate of 3-16 % for primary GB and 73-88 % for secondary GBs [10] . Other smaller studies have found a lower rate of IDH1 mutation in secondary GB of 50-67 % [19, 20] . Additionally, MD Anderson may have a higher incidence of low grade IDH1 wildtype tumors as these tumors typically behave more aggressively than low grade IDH1 mutated tumors. The malignant nature of lower grade IDH1 wildtype tumors may make these pts more likely to be referred to a dedicated brain tumor center. Similar to previous studies, pts with IDH1 mutated tumors were IDH1 wildtype tumors vs. 94 months for IDH1 mutated tumors (p = 0.0025).
For pts without an IDH1 mutation, median time from GB diagnosis to recurrent GB clinical trial in the cohort of pts with 6-PFS or RR was 8.48 and 8.44 months for the cohort of pts without 6-PFS or RR (p = 0.60). For pts with an IDH1 mutation, median time from GB diagnosis to recurrent GB clinical trial in the cohort of pts with 6-PFS and/or or RR was 19.84 and 6.46 months for the cohort of pts without 6-PFS or RR (p = 0.06).
Median PFS on a recurrent trial was 3.68 months for IDH1 wildtype GB vs. 3.52 months for IDH1 mutated GB (p = 0.72) (Fig. 2c) . Median OS on recurrent trial was 8.64 months for IDH1 wildtype GB vs. 9.59 months for IDH1 mutated GB (p = 0.49) (Fig. 2d) . Median PFS for only first recurrence pts was 3.3 months for IDH1 wildtype GB vs. 3.65 months for IDH1 mutated GB (p = 0.31). Median OS for only first recurrence pts was 9.38 months for IDH1 wildtype GB vs. 19.32 months for IDH1 mutated GB (p = 0.14) (Fig. 3) .
Discussion
Our study found that pts on clinical trials for recurrent GB with PFS-6 and/or RR were not more likely to be IDH1 mutated compared to a cohort of pts that failed to achieve PFS-6 or RR matched by clinical trial, age, and KPS. Additionally, IDH1 mutated tumors did not have a prolonged PFS or overall survival on recurrent GB trials compared to IDH1 wildtype tumors. These results would seem to indicate that An additional possible limitation was that over 70 % of the recurrent clinical trial regimens contained an anti-angiogenic agent. PFS-6 and RR were chosen as these are two of the most common endpoints used for determining response in recurrent GB clinical trials. RR as an endpoint for efficacy remains an area of debate when using anti-angiogenic agents [28] . While RR was seen in nearly all pts with PFS6, PFS6 was only seen in only around half of pts with RR. However, RR and PFS-6 were compared separately with their respective matched cohorts and the PFS6 group alone also did not appear to have a higher percentage of pts with an IDH1 mutation then its matched cohort.
Our study was further limited due to its retrospective nature. Although we attempted to match recurrent GB pts by clinical trial protocol, age and KPS, it is impossible to say if any slight differences in these factors may have influenced our results.
In conclusion, despite pts with IDH1 mutated gliomas having improved overall survival from initial tumor diagnosis, IDH1 mutations were not more common in pts with PFS-6 and/or RR on recurrent GB trials for this data set. This would seem to indicate that stratifying future recurrent GB trials based on IDH1 mutation status or excluding pts with IDH1 mutated tumors may be unnecessary if including pts at various recurrences. However, our findings suggest that stratification of pts based on IDH mutation status may potentially be necessary for recurrent GB clinical trials that limit patient enrollment to first recurrence. Due to the limitations in this retrospective review, further examination regarding the role of IDH1 mutation and response on recurrent GB clinical trials is needed in larger randomized prospective studies.
found to be diagnosed at a younger age and had an improved overall survival compared to IDH1 wildtype tumors of the same histopathologic grade.
One possible explanation that pts on clinical trials for recurrent GB with PFS-6 and/or RR were not more likely to have an IDH1 mutation compared to a matched cohort of pts without PFS-6 or RR is that treatment response in recurrent GB is likely dependent on more than just one genetic mutation. GB in particular is known to be a very heterogeneous tumor. A recent study has suggested that a combined analysis of mutations affecting the promoter region of the telomerase reverse transcriptase (TERT) gene, epidermal growth factor receptor (EGFR) amplification, and IDH status improves prognostic classes in GB [21] . Additionally, another study has suggested that the presence of an IDH1 mutation may not always indicate a favorable prognosis, as IDH1 mutated GBs also with a TERT mutation were found to have a poor prognosis [22] . It remains a possibility that if we examined more genomic abnormalities in addition to the IDH1 mutation that a combination of biomarkers could potentially predict response to treatment on recurrent trials.
Furthermore, lead time bias may have also been a factor in our study due to our inclusion of both GBs with an initial diagnosis of low grade or anaplastic tumors and GBs with initial diagnosis of GB. We decided to allow GBs with an initial diagnosis of low grade or anaplastic tumors in our study because they are currently included in recurrent GB trials. Pts with an initial diagnosis of low grade or anaplastic tumors occasionally received heterogenous treatments including radiation and/or a variety of chemotherapies prior to the diagnosis of GB as chosen by the treating physician. It is unclear the effect those earlier treatments may have had on the pts likelihood for response on later recurrent GB trials. However, overall survival from initial tumor diagnosis was similar for IDH1 mutated tumors regardless of whether they were in the cohort of pts with PFS-6 and/or RR or the matched cohort of pts without PFS-6 or RR (83.07 months vs. 86.07 months, p < 0.22).
Another potential limitation to our study was that only immunohistochemistry was used to determine IDH1 status. Although the concordance rate between immunohistochemistry and sequencing is reported to range from 88 to 99 %, a few studies have shown that the number of mutations detected by Sanger sequencing to be greater than those detected by immunohistochemistry [23] [24] [25] [26] . This discrepancy is thought to be due to immunohistochemistry failing to detect other types of IDH1 mutations including R132C, R132L, R132S, R132G, and IDH-2 mutations [27] . Additionally, by allowing tumors that had been biopsied only in our study, it is conceivable that the available tissue sample did not fully capture diagnostic material. There is also the possibility that specimens in which only a few scattered cells are R132H IDH1 immunopositive may not have the same properties as those with many more positive cells.
